TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02308202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxazosin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03686774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: no memantine
Description: Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment
Study: NCT02418546

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Nutritional Counseling by a Registered Dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling using an e-Health Application
Study: NCT04526691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
Study: NCT00834457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir/3TC/zidovudine
Description: continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir /3TC plus ritonavir boosted lopinavir
Description: fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
Study: NCT02628119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-procedural access flow
Description: Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Angioplasty
Description: Intervention based on 2 Dimensional fluoroscopy views
Study: NCT05087043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral motor stimulation (OMS) and The supplemental nursing system (SNS)
Description: OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
Study: NCT00590785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Study: NCT01772953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
Study: NCT01778192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: -group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: -group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate with magnesium citrate
Description: -group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
Study: NCT00590785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Study: NCT01778192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate with magnesium citrate
Description: -group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
Study: NCT00590785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
Study: NCT03725267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin Pill
Description: Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
Study: NCT00650637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: 1250 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide
Description: If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium carbonate not administered
Description: Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: nelfinavir 1250 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine + zidovudine
Description: lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
Study: NCT03883789

Intervention type: DIAGNOSTIC_TEST
Intervention: FibroScan
Description: FibroScan will be used to assess liver stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: FibroScan
Description: FibroScan will be used to assess liver stiffness
Study: NCT04824300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
Study: NCT02013323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing, and Septilin for 7 days
Description: Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
Study: NCT01294605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™ (dTpa)
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ditanrix™ Adult, TedivaxTM (Td)
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ditanrix™ Adult, TedivaxTM (Td)
Description: Intramuscular, 3 doses
Study: NCT02184169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments
Description: Breath to breath VO2 measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments
Description: Breath to breath VO2 measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr
Description: Edwards continuous SVO2 measurement system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr
Description: Edwards continuous SVO2 measurement system
Study: NCT00872573

Intervention type: DEVICE
Group type: OTHER
Intervention: C-Stem™ AMT Femoral Component (standard and high off-set variants)
Description: A polished triple tapered cemented femoral component for use in total hip replacement
Study: NCT04236635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Single Injection Technique
Description: CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Single Injection Technique
Description: CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Single Injection Technique
Description: CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Multiple Injection Technique
Description: CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Multiple Injection Technique
Description: CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum Multiple Injection Technique
Description: CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
Study: NCT01563393

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire STAMP and dietary
Description: Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The Placebo Comparator arm children got the classic care that practiced in hospitalization
Study: NCT03286400

Intervention type: DEVICE
Intervention: CTAG Device with ACTIVE CONTROL
Description: Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
Study: NCT00572169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Will be given in central venous catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Capsule taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A pill taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Study: NCT02013323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing, and Placebo drug for 7 days
Description: Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
Study: NCT02279303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
Study: NCT00572169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given into the vein (IV) by a continuous infusion through a central catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Study: NCT01469429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Receive lozenge placebo PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02279303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Control
Description: Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
Study: NCT01348529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT
Description: Internet-delivered cognitive behavioral therapy with therapist support.
Study: NCT03747029

Intervention type: OTHER
Intervention: No intervention is provided
Description: No intervention is provided

Intervention type: OTHER
Intervention: No intervention is provided
Description: No intervention is provided

Intervention type: OTHER
Intervention: No intervention is provided
Description: No intervention is provided
Study: NCT03397901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse colostomy
Description: Transverse double-cavity colostomy
Study: NCT03174977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Raltegravir
Description: A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
Study: NCT01469429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00572169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Study: NCT00061958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study: NCT02015377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar versus low sugar meals
Description: Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar versus low sugar meals
Description: Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
Study: NCT01748994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg per day for four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01987713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
Study: NCT01447628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intravenous, no active drug
Study: NCT04378933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber Glasses
Description: Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Lens Glasses
Description: Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
Study: NCT01447628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous, no active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject or CosmoFer
Description: Intravenous, 1000 mg iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject or CosmoFer
Description: Intravenous, 1000 mg iron
Study: NCT00338026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECO-4601
Description: Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
Study: NCT01777191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Auto-Injector
Description: Administered SC by auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Prefilled Syringe
Description: Administered SC by prefilled syringe
Study: NCT02591017

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo